TY - JOUR
T1 - A comparison of the chronic treatment effects of venlafaxine and other antidepressants on serotonin and norepinephrine transporters
AU - Gould, Georgianna G.
AU - Altamirano, Alfonso V.
AU - Javors, Martin A.
AU - Frazer, Alan
N1 - Funding Information:
This research was supported by funding from The National Institutes of Health (Grant MH57001; AF) and Wyeth Research (AF).We would like to thank Drs. Julie G. Hensler and David A. Morilak for their helpful suggestions about and reviews of this manuscript. Thanks to Dr. Saloua Benmansour, Mari Valdez, Dania Rossi, Gabriel Barrera, Erin May, Emily Maloney, Michella Saldana, Janea’ McDaniel and Lei Shi for their expert technical assistance.
PY - 2006/3/1
Y1 - 2006/3/1
N2 - Background: Venlafaxine blocks both serotonin and norepinephrine transporters (SERT and NET), with higher affinity for SERT. Serotonergic effects occur with lower doses, whereas both serotonergic and noradrenergic effects occur with higher doses of venlafaxine. Chronic treatment of rats with selective serotonin reuptake inhibitors decreases SERT binding sites, whereas similar treatment with selective norepinephrine reuptake inhibitors decreases NET binding sites. We hypothesizebd that venlafaxine would affect monoamine transporters dose-dependently, with low doses causing selective reduction of SERT binding sites and higher doses reducing both SERT and NET binding sites. Methods: Rats were treated for 21 days with a low (15 mg/kg/day) or high (70 mg/kg/day) dose of venlafaxine, vehicle, or other antidepressants. The SERT and NET density was determined by quantitative autoradiography. Results: Neither dose of venlafaxine nor amitriptyline reduced binding to either the SERT or NET. In rats with noradrenergic terminals destroyed by 6-hydroxydopamine, venlafaxine still failed to reduce SERT binding. Also, rats treated simultaneously with sertraline plus desipramine exhibited reductions in both SERT and NET binding. Conclusions: Chronic venlafaxine treatment affected SERT and NET binding differently from paroxetine or desipramine. The inability of venlafaxine to reduce SERT or NET binding sites is not due to its dual uptake inhibiting properties.
AB - Background: Venlafaxine blocks both serotonin and norepinephrine transporters (SERT and NET), with higher affinity for SERT. Serotonergic effects occur with lower doses, whereas both serotonergic and noradrenergic effects occur with higher doses of venlafaxine. Chronic treatment of rats with selective serotonin reuptake inhibitors decreases SERT binding sites, whereas similar treatment with selective norepinephrine reuptake inhibitors decreases NET binding sites. We hypothesizebd that venlafaxine would affect monoamine transporters dose-dependently, with low doses causing selective reduction of SERT binding sites and higher doses reducing both SERT and NET binding sites. Methods: Rats were treated for 21 days with a low (15 mg/kg/day) or high (70 mg/kg/day) dose of venlafaxine, vehicle, or other antidepressants. The SERT and NET density was determined by quantitative autoradiography. Results: Neither dose of venlafaxine nor amitriptyline reduced binding to either the SERT or NET. In rats with noradrenergic terminals destroyed by 6-hydroxydopamine, venlafaxine still failed to reduce SERT binding. Also, rats treated simultaneously with sertraline plus desipramine exhibited reductions in both SERT and NET binding. Conclusions: Chronic venlafaxine treatment affected SERT and NET binding differently from paroxetine or desipramine. The inability of venlafaxine to reduce SERT or NET binding sites is not due to its dual uptake inhibiting properties.
KW - Amitriptyline
KW - Dual uptake inhibitor
KW - Norepinephrine transporter
KW - Quantitative autoradiography
KW - Serotonin transporter
KW - Venlafaxine
UR - http://www.scopus.com/inward/record.url?scp=33344465355&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33344465355&partnerID=8YFLogxK
U2 - 10.1016/j.biopsych.2005.07.011
DO - 10.1016/j.biopsych.2005.07.011
M3 - Article
C2 - 16140280
AN - SCOPUS:33344465355
SN - 0006-3223
VL - 59
SP - 408
EP - 414
JO - Biological Psychiatry
JF - Biological Psychiatry
IS - 5
ER -